- The submission period is now open to individuals living with
migraine for the new AbbVie Migraine Career Catalyst
Award™ contest, awarding winners with a financial prize that
they may decide to use to support their career and professional
development goals
- As the only company with three treatment options designed to
meet patient needs across the spectrum of migraine, AbbVie is
dedicated to addressing the impact of migraine in the
workplace
NORTH
CHICAGO, Ill., June 6, 2024
/PRNewswire/ -- AbbVie (NYSE: ABBV) today launched the AbbVie
Migraine Career Catalyst AwardTM, a first-of-its-kind
contest designed to support the career, workplace, and professional
development aspirations of people living with migraine. With more
than 113 million workdays lost in the U.S. each year to the disease
and its symptoms, migraine can have a major impact in the
workplace.1 Twenty contest entrants will win up to
$2,500 that they can decide to use
toward career support, including career counseling, professional
development programs, and networking opportunities.
Visit the website to learn more and enter:
http://www.migrainecareercatalyst.com/.
"With the launch of the AbbVie Migraine Career Catalyst Award,
we're taking our commitment to the migraine community beyond the
medicine and hoping to empower migraine patients to pursue their
career goals with confidence," said Jag Dosanjh, senior vice
president, AbbVie, and president, neuroscience and eye care. "While
migraine has a significant impact on many areas of life, including
work, we are proud to support people living with the disease as
they strive for migraine freedom."
Migraine is the world's second leading cause of
disability2, impacting millions of people worldwide and
nearly 40 million in the U.S. alone.3 In the workplace
specifically, findings from the Chronic Migraine Epidemiology
and Outcomes (CaMEO) study, and more recent findings from the
CaMEO-International study, revealed substantial stigma against
people living with migraine, with many feeling that co-workers and
supervisors perceive their migraine attacks as an excuse to dismiss
responsibilities at work.4,5
"Common migraine symptoms – including extra sensitivity to
lights, sounds and smells, nausea, intense pain, difficulty
thinking clearly and more – can make it difficult or impossible to
work," said Dr. Dawn Buse, clinical
professor of neurology at Albert Einstein College of Medicine in
New York City, fellow of the
American Headache Society (AHS), and board member of the Headache
Cooperative of the Pacific (HCOP). "With the recent progress in
migraine management, people living with migraine have more options
than ever before to live their lives the way they want to, both in
the workplace and beyond. This contest helps to support that
objective."
Individuals living with migraine are invited to visit the
contest website at www.migrainecareercatalyst.com and follow
instructions to submit either (a) an essay not to exceed 3,000
characters in length, (b) a video up to three minutes in length, OR
(c) an audio clip up to three minutes in length that describes
their experience with migraine, their career goals, and how this
award might help them in their career.
The submission period for the AbbVie Migraine Career Catalyst
Award is now open and will close at 12:00
p.m. Eastern Time (ET) on Sept. 3,
2024. The winners will be announced on or about November 15, 2024. Please see full contest
Official Rules at http://www.migrainecareercatalyst.com/.
NO PURCHASE NECESSARY. OPEN TO LEGAL RESIDENTS OF THE FIFTY
UNITED STATES, D.C., AND
PUERTO RICO, AGE 18 OR OVER. VOID
WHERE PROHIBITED. APPROXIMATE RETAIL VALUE OF EACH PRIZE IS
$2,500.00 USD. ODDS OF WINNING DEPEND
ON NUMBER AND QUALITY OF ENTRIES RECEIVED. ENTRIES MUST BE RECEIVED
BEFORE 12:00PM ET ON 9/3/24.
ELIGIBILITY REQUIREMENTS AND RESTRICTIONS APPLY. PLEASE SEE FULL
CONTEST OFFICIAL RULES AT MIGRAINECAREERCATALYST.COM.
SPONSOR: ABBVIE INC.
About AbbVie in Migraine
AbbVie is the only company with three prescription treatments
designed to meet patient needs across the full spectrum of migraine
to help patients living with this debilitating disease. At AbbVie,
we are committed to empowering people living with migraine disease.
We advance science that enables healthcare providers to care for
people impacted across the spectrum of migraine. Through education
and partnerships with the migraine community, we strive to help
those with migraine navigate barriers to care, access effective
treatments and reduce the impact of migraine on their lives.
About AbbVie
AbbVie's mission is to discover and
deliver innovative medicines that solve serious health issues today
and address the medical challenges of tomorrow. We strive to have a
remarkable impact on people's lives across several key therapeutic
areas – immunology, oncology, neuroscience, and eye care – and
products and services in our Allergan Aesthetics portfolio. For
more information about AbbVie, please visit us
at www.abbvie.com. Follow @abbvie
on LinkedIn, Facebook, Instagram, X (formerly
Twitter), and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered,
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995. The words "believe," "expect,"
"anticipate," "project" and similar expressions and uses of future
or conditional verbs, generally identify forward-looking
statements. AbbVie cautions that these forward-looking statements
are subject to risks and uncertainties that may cause actual
results to differ materially from those expressed or implied in the
forward-looking statements. Such risks and uncertainties include,
but are not limited to, challenges to intellectual property,
competition from other products, difficulties inherent in the
research and development process, adverse litigation or government
action, and changes to laws and regulations applicable to our
industry. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2023 Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation, and specifically declines, to release publicly any
revisions to forward-looking statements as a result of subsequent
events or developments, except as required by law.
US-NEUM-240030
References
1 American Headache Society. Research Highlights
Impact of Migraine on Career Advancement and Financial Stability.
June 27, 2018. Accessed May 21, 2024.
https://americanheadachesociety.org/news/research-highlights-impact-migraine-career-advancement-financial-stability/
2 Steiner, T.J., Stovner, L.J., Jensen, R. et al.
Migraine remains second among the world's causes of disability, and
first among young women: findings from GBD2019. J Headache Pain.
2020 Dec;21:137.
3 American Migraine Foundation. What is migraine?
January 21, 2021. Accessed
January 31,
2024. https://americanmigrainefoundation.org/resource-library/what-is-migraine/
4 Buse DC, Shapiro RE, Lipton RB, et al. A
multi-country comparison of migraine-related stigma in people
living with migraine: results from the CaMEO-International Study.
Presented at the American Academy of Neurology (AAN) on
April 14, 2024.
5 Buse DC, Fanning KM, Lipton RB, et al. Life with
migraine: effects on relationships, career, and finances from the
chronic migraine epidemiology and outcomes (CaMEO) Study. Headache.
2019 Sep;59(8):1286-1299.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/abbvie-launches-first-of-its-kind-contest-to-empower-people-living-with-migraine-in-their-careers-302163834.html
SOURCE AbbVie